WallStSmart

Advanced Micro Devices Inc (AMD)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 70% more annual revenue ($58.74B vs $34.64B). AZN leads profitability with a 17.4% profit margin vs 12.5%. AMD appears more attractively valued with a PEG of 0.60. AZN earns a higher WallStSmart Score of 66/100 (B-).

AMD

Strong Buy

65

out of 100

Grade: B-

Growth: 7.3Profit: 6.0Value: 4.7Quality: 9.0
Piotroski: 6/9Altman Z: 3.74

AZN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMDSignificantly Overvalued (-80.3%)

Margin of Safety

-80.3%

Fair Value

$122.15

Current Price

$220.27

$98.12 premium

UndervaluedFair: $122.15Overvalued
AZNUndervalued (+32.8%)

Margin of Safety

+32.8%

Fair Value

$306.07

Current Price

$185.78

$120.29 discount

UndervaluedFair: $306.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMD6 strengths · Avg: 9.3/10
Market CapQuality
$334.84B10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
34.1%10/10

Revenue surging 34.1% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.7410/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.608/10

Growing faster than its price suggests

Free Cash FlowQuality
$2.38B8/10

Generating 2.4B in free cash flow

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$284.63B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

AMD3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.2%4/10

2.2% earnings growth

Return on EquityProfitability
7.1%3/10

ROE of 7.1% — below average capital efficiency

P/E RatioValuation
78.7x2/10

Premium valuation, high expectations priced in

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMD

The strongest argument for AMD centers on Market Cap, Revenue Growth, Debt/Equity. Revenue growth of 34.1% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : AMD

The primary concerns for AMD are EPS Growth, Return on Equity, P/E Ratio. A P/E of 78.7x leaves little room for execution misses.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

AMD profiles as a growth stock while AZN is a value play — different risk/reward profiles.

AMD carries more volatility with a beta of 2.02 — expect wider price swings.

AMD is growing revenue faster at 34.1% — sustainability is the question.

AMD generates stronger free cash flow (2.4B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (66/100 vs 65/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Micro Devices Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Advanced Micro Devices, Inc. (AMD) is an American multinational semiconductor company based in Santa Clara, California, that develops computer processors and related technologies for business and consumer markets. AMD's main products include microprocessors, motherboard chipsets, embedded processors and graphics processors for servers, workstations, personal computers and embedded system applications.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?